Abstract
Background: The thrombolytic agent tissue plasminogen activator (tPA) is underutilized in ischemic stroke, in part because of its limited therapeutic window and hemorrhagic complications. Identifying an adjuvant drug that reduces the risk of hemorrhage could increase the applicability of tPA. Studies have shown that A2b receptor (A2bR) can regulate vascular leakage reduce MMP9 expression, so A2bR is the potential target.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
